Boehringer Ingelheim Secures EU Nod for JASCAYD®, First Novel Oral Treatment for IPF and PPF in Over a Decade
Event summary
- The European Commission approved JASCAYD® (nerandomilast), a novel oral treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).
- This marks the first new IPF treatment approved in the EU in over a decade and the first for PPF in more than five years.
- Phase III FIBRONEER™ trials demonstrated nerandomilast slowed lung function decline with a favorable safety profile, showing similar discontinuation rates to placebo.
The big picture
Boehringer Ingelheim’s JASCAYD® approval addresses a critical unmet need in IPF and PPF, where treatment options have been limited. The drug’s novel mechanism and tolerability could reshape the competitive landscape for pulmonary fibrosis therapies. With over 500,000 affected individuals in Europe alone, this approval positions Boehringer Ingelheim to capture significant market share in a space dominated by older treatments with notable side effects.
What we're watching
- Market Penetration
- How Boehringer Ingelheim will position JASCAYD® against existing therapies given its favorable tolerability profile.
- Regulatory Expansion
- The pace at which nerandomilast gains approvals in other major markets, with submissions under review globally.
- Pipeline Potential
- Whether Boehringer Ingelheim can leverage the PDE4B inhibitor mechanism for systemic sclerosis and myositis.
Related topics